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Abstract
Introduction: Medulloblastoma (MB) is the most common malignant paediatric brain tumour. Recurrence and
progression of disease occurs in 15-20% of standard risk and 30-40% of high risk patients. We analysed whether
circumvention of chemoresistance pathways (drug export, DNA repair and apoptotic inhibition) can restore
chemotherapeutic efficacy in a panel of MB cell lines.
Results: We demonstrate, by immunohistochemistry in patient tissue microarrays, that ABCB1 is expressed in 43% of
tumours and is significantly associated with high-risk. We show that ABCB1, O6-methylguanine-DNA-methyltransferase
(MGMT) and BCL2 family members are differentially expressed (by quantitative reverse transcription polymerase chain
reaction, Western blotting and flow cytometry) in MB cell lines. Based on these findings, each pathway was then
inhibited or circumvented and cell survival assessed using clonogenic assays. Inhibition of ABCB1 using vardenafil or
verapamil resulted in a significant increase in sensitivity to etoposide in ABCB1-expressing MB cell lines. Sensitivity to
temozolomide (TMZ) was MGMT-dependent, but two novel imidazotetrazine derivatives (N-3 sulfoxide and N-3
propargyl TMZ analogues) demonstrated ≥7 fold and ≥3 fold more potent cytotoxicity respectively compared to TMZ
in MGMT-expressing MB cell lines. Activity of the BAD mimetic ABT-737 was BCL2A1 and ABCB1 dependent, whereas
the pan-BCL2 inhibitor obatoclax was effective as a single cytotoxic agent irrespective of MCL1, BCL2, BCL2A1, or
ABCB1 expression.
Conclusions: ABCB1 is associated with high-risk MB; hence, inhibition of ABCB1 by vardenafil may represent a valid
approach in these patients. Imidazotetrazine analogues of TMZ and the BH3 mimetic obatoclax are promising clinical
candidates in drug resistant MB tumours expressing MGMT and BCL2 anti-apoptotic members respectively.
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Introduction
Medulloblastoma (MB) is the most frequent primary ma-
lignant brain tumour in children [1]. Currently the MB
clinical staging system differentiates between standard-risk
or high-risk disease depending on clinical findings and
histologic subtype [2,3]. Standard risk describes children
older than 3 years of age at diagnosis with totally or near
totally resected, non-disseminated disease and classic or
desmoplastic histology. High-risk patients have either
disseminated disease, incomplete resection or are of the
large cell or anaplastic histologic subtypes [4,5]. Treatment
generally consists of gross total surgical excision combined
with radiotherapy and chemotherapy; however 30-40% of
high risk and 15-20% of standard risk patients develop
recurrence of disease resulting in poor survival outcome
[1,3,6-12]. Long term survivors suffer from treatment-
associated endocrine, neurological, growth and neurocog-
nitive complications that affect quality of life, in addition to
having a substantial risk of secondary malignancy [13,14].
From a chemotherapy perspective, primary MBs are
mainly treated with combination chemotherapies that in-
clude: etoposide, methotrexate, cisplatin, lomustine, cyclo-
phosphamide and vincristine [11,15-17]. Recurrent and
progressive tumours in children are treated with more in-
tensive regimes frequently involving temozolomide (TMZ)
and irinotecan although the prognosis for these patients is
poor [1,18-22].
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Chemotherapy is now widely accepted as part of
standard therapy for MB. The high frequency of recur-
rence, however, supports the hypothesis that a substan-
tial number of patients have intrinsically drug resistant
tumours [23]. Chemotherapy treatment failure is par-
ticularly relevant in children under three years of age
who are preferentially treated with chemotherapy alone
to minimise the adverse effect of radiotherapy on the de-
veloping brain [16,24-26].
Classical multidrug resistance is often partly attributed
to elevated expression of polyspecific ATP-dependent
drug efflux pumps belonging to the ATP-binding cas-
sette (ABC) transporter super family. The three best
characterised are ABCB1 (also known as P-glycoprotein
or MDR1), ABCG2 (Breast Cancer Resistance Protein)
and ABCC1(multidrug resistance associated-protein 1 or
MRP1) reviewed by Szakács et al. [27]. High expression
of ABCB1 has previously been associated with chemore-
sistance and poor outcome in brain tumours including
MB [28], glioma [29] and ependymoma (manuscript in
preparation). We have also previously demonstrated that
ABCB1 is expressed in a small subset of brain tumour
cells and hypothesised that these cells are selected by
current treatments resulting in relapse [30]. Since four
of the drugs currently being used to treat primary and
recurrent MB are ABCB1 substrates (etoposide, vincris-
tine, methotrexate and irinotecan) [27] we would antici-
pate that overcoming/inhibiting ABCB1 could enhance
the efficacy of current chemotherapy regimens.
Lomustine and TMZ are oral DNA alkylating cytotoxic
drugs used for the treatment of primary and recurrent MB,
respectively. The activity of both drugs depends on the
absence of direct repair by O6-methylguanine-DNA-meth-
yltransferase (MGMT) and proficient mismatch repair
(MMR) [31]. Thus, over-expression of MGMT, a feature of
more than half of MB patients in two recent studies
[32,33] can diminish the therapeutic efficacy of TMZ and
lomustine. However, methylation of O6-guanine, the major
cytotoxic lesion, comprises only 6% TMZ-DNA adducts
[34], TMZ also methylates N7-guanine and N3- adenine,
generating lesions which are repaired by base excision re-
pair (BER) facilitated by the enzyme poly ADP ribose poly-
merase (PARP). Inhibition of PARP has been shown to
enhance TMZ activity in vitro and in vivo [35,36]. Re-
cently, an alternative single agent approach has been
shown to circumvent MGMT-mediated resistance in glio-
blastoma cell lines using novel imidazotetrazine TMZ ana-
logues [37]. We wished to examine whether these agents
were also able to effectively kill MB cells expressing high
levels of MGMT.
Chemotherapy-induced cell cytotoxicity mainly occurs
via the mitochondrial apoptotic pathway, regulated by
the B-Cell lymphoma/leukaemia 2 (BCL2) family. Over-
expression of anti-apoptotic BCL2 family proteins, such
as BCL2, BCL-XL, MCL1 and BCL2A1, has been observed
in many types of cancer including MB [38-41]. Hence,
since the cloning of BCL2 25 years ago [42] many at-
tempts have been made to target these pro-survival onco-
genes therapeutically [43]. The most successful approach
to target this pathway has been through the use of BCL2
homology 3 (BH3) mimetics; small molecules designed to
mimic the BH3 domain found in pro-apoptotic members
of the BCL-2 family. Recently two such small molecule in-
hibitors (ABT-737/ABT-263 and obatoclax) have entered
clinical trial [44,45]. We have previously tested ABT-737
on MB cell lines in vitro and although it was able to po-
tentiate the action of cisplatin and etoposide, it proved in-
effective as a single agent [46]. ABT-737 is described as a
BAD mimetic since it shows the same binding to BCL2,
BCL-XL and BCL-w as this BH3 pro-apoptotic protein.
We needed to determine whether the lack of ABT-737
efficacy as a single agent was due to the expression of
additional BCL2 family members, targetable by the pan-
inhibitor obatoclax, or the fact that ABT-737 has recently
been demonstrated to be an ABCB1 substrate in chronic
lymphocytic leukaemia [47].
In this study we set out to investigate three potential
reasons for chemotherapy failure in MB using a combin-
ation of patient tissue microarrays and early passage cell
lines. We show that whilst all three mechanisms do in-
deed contribute to MB chemoresistance, each of them
can be effectively circumvented using a combination of
novel agents (vardenafil, N3-propargyl and obatoclax).
Materials and methods
Patient characteristics
Clinical and histological data for the Nottingham retrospect-
ive cohort are outlined in the Additional file 1: Table S1.
Clinical details of patients included in tissue microarrays
(TMA) obtained from German Cancer Research Centre
DKFZ were previously published by Dubuc et al. [48].
Cell culture
Five new primary and recurrent (R) MB cell lines were
derived as previously described [30] at the Children’s
Brain Tumour Research Centre (CBTRC) (MED3, MED4,
MED4R, MED5R and MED6) with approval from Local
Research Ethics Committee. The tumours of origin were
classified into molecular subtypes according to recent
classification of MB subtypes [49-51]. Primary MB cell
lines were cultured as monolayers and neurospheres as
described previously [30]. The DAOY MB cell line was
purchased from ATCC and cultured as recommended.
UW228-3 was supplied by John R. Silber and grown as
recommended [52]. A control Human Embryonic Kidney
cell line (HEK-B1) stably expressing ABCB1 was provided
as a gift by Rob Robey and cultured in DMEM with 10%
serum and 500 μg/ml of G418.
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Immunohistochemistry
Immunohistochemistry (IHC) was performed using the
Dako Envision Detection kit (DAKO REAL EnVision) [53].
Sections were counter-stained with haematoxylin (Leica
Microsystems). As negative controls, adjacent or similar
sections were processed with antibody diluent (Dako). The
antibodies (Abs) used to stain the original patient samples
with appropriate control for each Ab are summarised in
Additional file 2: Table S2.
A total of 27 Nottingham MB patients diagnosed be-
tween January 1986 and January 2006 were analysed by
IHC. Consent for tumour tissue use was taken in accord-
ance with national tumour banking procedures (UK: 05/
MRE/04/70). A second TMA comprising 233 patient sam-
ples was obtained from the DKFZ [48]. Both TMAs were
stained with the anti-ABCB1 Ab (C219, 1:40; Calbiochem)
and patients with clear evidence of cell membrane staining
were scored as positive by three independent reviewers
who were blinded to clinical and patient molecular
variables.
Detection of ABCB1 expression and inhibition of ABCB1
function by flow cytometry
To detect the percentage of ABCB1 expressing cells,
300,000-500,000 cells were incubated with 4E3 (anti-
ABCB1; 1:20; Abcam) for 30 minutes at 37°C in fluores-
cent activated cell sorting (FACS) buffer (high glucose
DMEM plus 5% BSA). The cells were then washed twice
with FACS buffer and incubated with Alexa Fluor® 647
goat anti-mouse IgG (1: 1000; Invitrogen) for 30 minutes
on ice in the dark. As a control, cells were stained with
secondary Ab alone (Alexa Fluor 647; Invitrogen). Any
unbound Ab was removed by washing the labelled cells
twice with FACS buffer. To investigate ABCB1 function,
cells were incubated with Rhodamine 123 (Rh123, Sigma;
ABCB1 flourescent substrate), with and without ABCB1
inhibitors verapamil (VPL, Sigma), and vardenafil (TRC-
Canada) at concentrations given in figure legends. Fluores-
cence was detected on a Cytomics FC500 flow cytometer
(Beckman Coulter) and analysed using WinMDI version
2.8. Data presented are mean ± SEM of three independent
experiments.
Quantitative polymerase chain reaction
RNA extraction from cultured cells was performed using
mirVana miRNA Isolation kit (Ambion) and transcribed
into cDNA using reverse transcriptase (Superscript III;
Invitrogen). The resulting cDNA template was amplified
and sequenced using primers previously published by
Kumar et al. [54]. PCR products were sequenced on the
forward and reverse strands at the DNA sequencing lab
at the University of Nottingham.
Quantitative reverse transcription PCR (QRT-PCR)
analysis was carried out using the CFX96 real time PCR
machine (BIO-RAD) and iQ SYBR Green SuperMix
(BIO-RAD) to assess the expression. Primers for MB
molecular subtyping (WIF1, SFRP1, NPR3 and KCNA1)
were designed and published by Zhao et al. [55]. ABCB1
primers were as published by Valera et al. [56]. The
house-keeping gene GAPDH (Forward primer 5′ ATGT
TCGTCATGGGTGTGAA 3′; reverse primer 5′GTCT
TCTGGGTGGCAGTGAT 3′) was used as a control to
normalise the data, as the cycle threshold value for
GAPDH expression was consistent across the sample set.
Relative values of transcripts were calculated using the
Pfaffl equation [57]. Results are presented as mean ± SEM
of three independent experiments, each experiment was
performed in triplicate.
To identify MYCC and MYCN copy number elevation
in MB samples, genomic DNA extraction from frozen
cell pellets was performed as previously described [30].
Quantitative PCR (QPCR) analysis was carried out using
the CFX96 real time PCR machine (BIO-RAD) and iQ
SYBR Green SuperMix (BIO-RAD). DNA isolated from
D458 cells was used as a positive control for MYCC and
a previously described sample of anaplastic astrocytoma
with MYCN amplification was used as a positive control
for MYCN [58]. MYCC and MYCN copy numbers were
measured relative to the endogenous control RPLP0 and
results for each sample were normalised to the copy
number of diploid human DNA in Pfaffl equation [57].
Primer sequences have been previously published by
Ryan et al. [59].
Western blotting
SDS PAGE and Western blotting were performed as
previously described [46]. Blots were probed with the
following Abs: mouse anti-ABCB1 (anti-C219 mouse
monoclonal Ab; Calbiochem1:100), anti-MGMT (Millipore
1:100), rabbit anti-BCL2 (Cell Signaling clone 50E3
1:1000), rabbit anti BCL2A1 (Cell Signaling 1:1000),
Rabbit anti-MCL1 (Santa Cruz 1:500) and either mouse
anti-GAPDH (Sigma) or rabbit anti-β-tubulin (Cell Signal-
ling Technology) 1:1000 as loading controls. All primary
Abs were detected using goat anti-mouse/rabbit IgG HRP-
linked secondary Ab (Cell Signalling Technology 1:2000)
and enhanced chemoluminescence (GE Health Care Life
Science) performed according to the manufacturer’s
protocol.
Clonogenic assay
Cell growth inhibition was estimated after treatment of
single cells in 6 well plates. Cells (150–200) were seeded
into 6 well plates, and allowed to adhere (4–8 hours) be-
fore drug treatment. At the outset the clonogenic range
was established for each drug and used to derive IC50
drug concentrations. The range of drug concentrations
tested and the length of the treatment period was
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dependent on the drug being tested. Cells were incubated
with: 0–8 μM etoposide (Sigma) for 2 hours; 0–50 μM
ABT-737 (Benzamide; Selleckchem) for 24 hours; 0–3 μM
obatoclax mesylate (GX15-070; Geminx) for 24 hours;
0–800 μM (MGMT+) or 0–100 μM (MGMT-) TMZ for
2 hours; and up to 200 μM N-3 sulfoxide and N-3 propar-
gyl for 2 hours. Inhibitors were added for the same length
of time as the drug, either in the same well or separately to
assess toxicity. For experiments to investigate the role of
ABCB1 in mediating drug resistance; verapamil (10, 20 μM
Sigma) and vardenafil (5, 10 μM Toronto Research Chemi-
cals) were tested. To investigate potentiation of TMZ or
N3-propargyl by circumvention of BER the PARP inhibitor
rucaparib (0.4 μM AG 014699; Selleckchem) was tested.
Following drug +/− inhibitor addition, the cultures were
then maintained at 37°C in a humidified atmosphere con-
taining 5% v/v CO2, and allowed to grow for 6 (MED1), 7
(DAOY and UW228-3), or 12 (MED3) days depending on
the cell line’s doubling time. Colonies were fixed with
4% w/v paraformaldehyde and stained with 0.1% w/v crys-
tal violet (Sigma). Colonies that contained more than 50
cells (≥6 doublings) were counted. The colonies were
double-scored (one of the scorers being blind to the cul-
ture conditions). Clonogenic assays were repeated at least
three times as independent experiments, each with internal
duplicate cultures. The percentage of clonogenic survival
was expressed relative to vehicle controls.
Statistical analysis
Log-rank analysis on Kaplan–Meier curves determined
the significance of overall survival (OS) and progression
free survival (PFS) using SPSS version 21 statistical soft-
ware (IBM). Differences between pairs of groups were
determined by the Student’s t-test or Chi-squared test
using GraphPad prism version 5.00 (San Diego Califor-
nia, USA) or IBM SPSS version 21 respectively. Re-
sponse to TMZ and TMZ analogues between groups
was assessed using one way ANOVA. P values < 0.05
were considered significant.
Results
ABCB1 expression is associated with high risk MB
There is evidence supporting a role for MGMT and the
BCL2 family in MB chemotherapeutic response; how-
ever, the evidence supporting ABCB1 was more equivo-
cal [28,33,41]. We therefore set out to identify whether
there were clinical correlates of ABCB1 expression in a
retrospective Nottingham MB patient TMA. In total 12
of 27 samples (44%) were positive for ABCB1 expres-
sion, and the majority of these were high risk patients,
but this relationship was not statistically significant (P ≥
0.05), presumably due to the small number of patient
samples. We then analysed ABCB1 expression across a
larger German DKFZ TMA. On this array 42% (99/233)
of samples were positive for ABCB1 expression and
ABCB1 was significantly more likely (P = 0.035) to be
expressed in samples from high risk patients (Figure 1A).
There was no significant difference between age, gender,
resection status, and recurrence group of the two studies
(P > 0.05, Additional file 3: Table S3). In each case positive
samples contained a subpopulation of cells with mem-
branous ABCB1 expression (0.1-11%). This high frequency
of ABCB1 expression in MB patients and association with
high risk clearly justified its inclusion in our chemoresis-
tance analyses of patient derived cell lines.
Characterisation of MB cell lines and their tumour of origin
To investigate the mechanisms of drug resistance in MB,
we have adopted an approach that involves establishing
cell lines from patients’ primary and recurrent tumours
[30]. In the current work, we describe 6 newly derived MB
cell lines (including the previously described MED1) [30].
The clinical characteristics of these patients are presented
in supplementary Additional file 4: Table S4. The tumours
from which the cell lines were derived have been assigned
to MB molecular subtypes [60,61] using IHC for β-
catenin, Gli1, NPR3 and KCNA1 (Additional file 5: Figure
S1), and sequencing of the β-catenin gene (CTNNB1). The
corresponding cell lines were sub-grouped by comparing
expression of representative genes [WIF1 (WNT), SFRP
(SHH), NPR3 (Group 3), and KCNA1 (Group 4)] to foetal
cerebellum (Additional file 6: Figure S2, [55]). MYCC and
MYCN copy number were determined (Additional file 7:
Figure S3) and β-catenin sub-grouping was again confirmed
by sequencing CTNNB1 (Additional file 8: Figure S4).
These data are summarised in Table 1. Our data therefore
suggest that MED1 is derived from a large cell anaplastic
Group 4 tumour with MYCN amplification. MED3 is de-
rived from a classical Group 3 tumour, MED4, and MED4R
result from Group 3 tumours with MYCN gain. In each
case the cell lines maintain the characteristics of their
tumour of origin. MED5R and MED6 are derived from
WNT subtypes (β-catenin positive) large cell anaplastic and
classical tumours respectively. MED5R and MED6 have
heterozygous mutations (TCT-TTT) at codons 33 and 37
(of CTNNB1) respectively. The MED5R cell line main-
tained the mutation in culture whereas the MED6 cell line
reverted to wild type (Additional file 8: Figure S4). We also
established that UW228-3 cells are NPR3 positive with
MYCC gain. DAOYcells, on the other hand proved difficult
to classify, although, have been classified recently as SHH
by Pambid et al. [62].
ABCB1 expression and function is maintained in MB cell
lines
ABCB1 expression was assessed in each of the tumours
of origin by IHC (Additional file 9: Figure S5). The per-
centage of ABCB1 expressing cells ranged from ~1% in
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the MED6 to 11.2% in the MED1 tumour of origin
(Table 1). ABCB1 expression was then assessed in the 6
CBTRC cell lines derived from these MBs as well as
two more generally studied MB cell lines, DAOY and
UW228-3, by QRT-PCR (Figure 1B). In common with
the tumour of origin, MED1 cells expressed the highest
levels of ABCB1 mRNA (Figure 1B) and glycosylated
ABCB1 protein (Additional file 10: Figure S6), thus con-
firming maintenance of ABCB1 expression in culture.
MED4, MED4R and MED5R demonstrated intermediate
ABCB1 expression whereas MED3 cells expressed negli-
gible mRNA and protein, again correlating with protein ex-
pression levels in primary tumours (Figure 1B, Additional
file 10: Figure S6, Table 1). DAOY cells showed intermedi-
ate ABCB1 expression, whereas UW228-3 cells expressed
low ABCB1 mRNA and protein levels. Three cell lines
demonstrating high (MED1), intermediate (DAOY) and
low (MED3) ABCB1 expression were further investigated
for cell surface expression and function of ABCB1 by flow
cytometry and compared to HEK-B1 cells stably expressing
MED1 MED3HEK-B1 DAOYC)
A)
D)
92.6  ±3.7 5.8  ±1.2 0.6 ±0.4
2.4 ±0.5
60.4  ±9.6
62.4  ±6.5
3.5  ±0.2
3.2 ±0.16
1.7 ±0.2
1.3 ±0.2
E)
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Rh123+ VPL 
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R
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e 
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1 
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ABCB1 
immunonegative
ABCB1 
immunopositive
Complete 
cohort
Fisher’s 
Exact 
Test
Variable No. % No % No. (%) P value
Risk group
Standard 47 44 23 28 70 (37)
P= 0.035
High 60 56 58 72 118 (63)
4E3
Figure 1 ABCB1 expression and functional analysis. (A) Membranous ABCB1 expression was scored across the DKFZ TMA and correlated with
treatment risk group in 188 patients >3-17 years old. ABCB1 was significantly more likely (P ≤ 0.035) to be expressed in samples from high risk
patients. (B) Relative expression of ABCB1 was calculated for each cell line using MED3 as a calibrator and GAPDH as a house keeping gene in
the Pfaffl equation [57]. ABCB1 is expressed in 6/8 MB cell lines. Data are expressed as the mean ± SEM of three experiments, each performed in
triplicate. (C) Flow cytometry analysis of ABCB1 cell surface expression was carried out on MED1, MED3, DAOY and HEK-B1 control cell lines
stained with anti-ABCB1 antibody (clone 4E3; unfilled histogram) or secondary antibody alone (filled histogram). Although only 5.8% of MED1 cells
are positive for ABCB1 some cells expressed very high levels whereas MED3 showed no expression of ABCB1 (0.6 ± 0.4%). Representative dotplots
can be found in Additional file 11: Figure S7. (D, E) ABCB1 function was tested by flow cytometry. Cells were incubated with either Rh123 alone
(filled histogram) or in combination with VPL (D) or vardenafil (E) shown as unfilled histograms in each case. Inhibition of ABCB1 function was
observed in 3.5% of MED1 cells consistent with the low% of cells expressing ABCB1. Similarly, there was no inhibition of function in MED3 cell
line. Results in (C-E) represent mean ± SEM of three independent experiments.
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ABCB1 (Figure 1C-E). For MED1 5.8 ± 1.2% cells were
positive for ABCB1 with some cells showing very high ex-
pression (Figure 1C, Additional file 11: Figure S7). MED3
cells demonstrated negligible ABCB1 expression (0.6 ±
0.4%). Within the DAOY cell population 2.4 ± 0.5% cells
expressed consistently low ABCB1 levels (See Figure 1C,
Additional file 11: Figure S7). ABCB1 function was investi-
gated with the Rh123 extrusion assay. Extrusion of Rh123
in MED1 was inhibited by 20 μM VPL (right shifted cell
histogram) and 10 μM vardenafil (Figure 1D,E) in ~3.5% of
cells. Thus both agents are able to inhibit Rh123 extru-
sion in 60% of ABCB1 expressing (3.5/5.8) cells. Similar
levels of inhibition (54-66%) were observed with both
inhibitors in HEK-B1 and DAOY cells. MED3 cells failed
to extrude Rh123 consistent with lack of ABCB1 cell
surface expression.
Co-treatment with ABCB1 inhibitors VPL and vardenafil
results in increased etoposide cytotoxicity
To further investigate ABCB1 function in vitro, clonogenic
survival was assessed in ABCB1 negative MED3 and 2
ABCB1 positive (MED1 and DAOY) MB cell lines in re-
sponse to etoposide alone or in combination with the
ABCB1 inhibitors VPL and vardenafil. The IC50 concen-
trations for etoposide reflected the expression levels of
ABCB1, with MED1 demonstrating the greatest degree of
resistance to etoposide (MED1 1.92 μM, DAOY 1 μM,
and MED3 0.5 μM) (Figure 2). Both ABCB1-expressing
cell lines demonstrated significantly increased etoposide
sensitivity when cells were treated with etoposide at the
IC50 concentration plus inhibitors VPL or vardenafil com-
pared to cells treated with etoposide alone (MED1 P <
0.0001 in all cases, Figure 2A; DAOY P < 0.001 in all cases
except 5 μM vardenafil P = 0.02; Figure 2B). Conversely,
no significant potentiation of cell cytotoxicity was ob-
served when MED3 cells were treated with etoposide plus
ABCB1 inhibitors (P > 0.05; Figure 2C). These results
confirm that etoposide cytotoxicity in MB cell lines is sig-
nificantly influenced by ABCB1 expression. Moreover, our
in vitro assays confirm that vardenafil significantly inhibits
ABCB1.
Obatoclax-induced apoptosis in MB cell lines is
independent of MCL1, BCL2A1 and ABCB1 expression
We have previously shown that MB cell lines express
MCL1 and BCL2 anti-apoptotic proteins, and that the
BH3 mimetic ABT-737, although able to potentiate activ-
ity of chemotherapeutic drugs, failed to induce apoptosis
as a single agent in MB cell lines [46]. The lack of efficacy
of ABT-737 could not be explained by BCL2 and MCL1
expression alone. Therefore we sought to further investi-
gate the efficacy of ABT-737 against MB cell lines and
compare it to the new anti-BCL2 drug obatoclax. We first
looked at anti-apoptotic (BCL2, MCL1 and BCL2A1) pro-
tein expression in three representative MB cell lines, in-
cluding UW228-3 since this was used in our previous
study (Figure 3A). Whereas BCL2 and MCL1 were differ-
entially expressed, consistent with our previous report
[46], all 3 cell lines expressed BCL2A1. Previous studies
on leukaemia cell lines have shown that ABT-737 is a sub-
strate for ABCB1 [47], therefore the pro-apoptotic activity
of ABT-737 and obatoclax were tested on these 3 cell lines
with and without the ABCB1 inhibitor VPL (Figure 3B,
C). ABT-737 was tested up to maximum 50 μM concen-
tration (DMSO> 0.1%) but it was only able to reduce cell
colony formation by approximately 20%, 15% and 20% in
DAOY, MED1 and UW228-3 respectively. There was a
small but significant increase in ABT-737 efficacy when
ABCB1 positive MB cells were treated with ABT-737
(50 μM) plus 10 μM of VPL (P < 0.03 for MED1 and P <
0.02 for DAOY; Figure 3B) but no effect of VPL was found
on ABCB1 negative UW228-3 cells (P ≥ 0.05). Obato-
clax caused significantly decreased clonogenic cell sur-
vival resulting in less than 2% clonogenic survival at the
Table 1 Characterisation of MB original patient samples and their derived cell lines
Name Tumour Cell lines
Histology IHC MB subtype
marker
CTNNB1
mutated
IHC
ABCB1 %
IHC
MGMT
MB
subtype
Subtype
QRTPCR
MYC status CTNNB1
mutated
MB
subtype
MED 1 LC/A KCNA1 No 11.2 - Group 4 KCNA1 positive MYCN Amplified No Group 4
MED 3 Classical Moderate NPR3 No 0 + Group 3 NPR3 positive Normal No Group 3
MED4 LC/A NPR3 No 1.9 + Group 3 NPR3 positive MYCN gain No Group 3
MED4R LC/A NPR3 No 4.5 + Group 3 NPR3 positive MYCN gain No Group 3
MED5R LC/A β-catenin Yes 6.2 + WNT* NPR3 positive Normal Yes WNT
MED6 Classical β-catenin Yes 1.2 + WNT* NPR3 positive Normal No Group 3
UW228-3 Classical NA NA NA NA Group 3 NPR3 positive MYCC gain No Group 3
DAOY Desmoplastic NA NA NA NA SHH? None Normal No SHH [62]**
Abbreviation: LC/A = large cell/anaplastic medulloblastoma, R=recurrent, IHC = immunohistochemistry, WNT = β-catenin positive, Group 3 = NPR3 positive,
Group 4= KCNA1 positive, MED4 and MED4R are from the same patient.
*Frozen tissue from MED5R and MED6 has CTNNB1 mutation at codon 33 and 37 respectively. NA= tumour material not available. **DAOY cell line was
characterised as SHH by Pambid et al. [62].
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highest concentration (3 μM) in all 3 cell lines (Figure 3C).
The IC50 of obatoclax in DAOY, MED1 and UW228-3
was 0.27, 0.3 and 0.42 μM respectively. Most importantly,
there was no significant change in colony formation fol-
lowing treatment of cells with obatoclax and VPL (P >
0.05; Figure 3C). Our in vitro results suggest that obato-
clax is not an ABCB1 substrate; can inhibit BCL2, MCL1
and BCL2A1, and therefore, is more effective than ABT-
737 since it can function as a single agent.
Growth inhibition by the two novel TMZ analogues
(N-3 sulfoxide and N-3 propargyl) is MGMT independent
TMZ cytotoxicity depends on the absence of MGMT en-
zyme and functioning MMR [31]. MGMT expression was
assessed in all tumours of origin for our cell lines by IHC
(Additional file 12: Figure S8, Table 1). Only MED1 was
MGMT negative, with all other samples showing strong
MGMT expression. DAOY, UW228-3 and MED3 MB cell
lines all show high MGMT expression while MED1 cells
show no MGMT expression by Western blotting, consist-
ent with the observed expression in primary tissue samples
from the corresponding tumours (Figure 4A, Additional
file 12: Figure S8). The efficacy of TMZ and two novel
imidazotetrazine TMZ analogues (N-3 sulfoxide and N-3
propargyl; Figure 4B) were compared using the clonogenic
assay. Clonogenic survival was concentration-dependent
in all 4 cell lines. DAOY, UW228-3 and MED3 were resist-
ant to TMZ (IC50 = 290–540 μM; Figure 4C); in contrast
MED1 cells were sensitive (IC50 = 31 μM; Figure 4C). All
MB cell lines were sensitive to sulfoxide and propargyl
٭ ٭ ٭
A) VPL Vardenafil
IC50 = 1.92  μM
B)
٭٭
٭
٭٭
IC50 = 1 μM
C)
IC50 = 0.5 μM
٭ ٭ ٭
٭ ٭ ٭
٭ ٭ ٭
٭ ٭ ٭
MED1
DAOY
MED3
Etoposide
μM VPL
μM vardenafil
+ + +-- + + +--
- 10 202010
- 5 10105
-- -- -
-- -- -
Figure 2 Clonogenic survival analysis of MB cells treated with etoposide in the presence of ABCB1 inhibitors. The left panel shows the
effect of increasing etoposide concentrations on clonogenic survival (100% representing solvent control). The middle and right panels represent
clonogenic survival in the presence of etoposide (IC50 concentrations derived from dose–response data) in combination with VPL (10 and 20 μM)
or vardenafil (5 and 10 μM) respectively. (A) MED1 clonogenic survival is significantly inhibited in cells co-treated with etoposide and VPL or
vardenafil (unpaired student’s t-test, ٭٭٭ P < 0.0001 in all cases). (B) There was also a significant increase in etoposide cytotoxicity in DAOY cells
when combined with VPL and vardenafil (unpaired student’s t-test, ٭٭ P < 0.001; ٭P = 0.02). (C) No significant inhibition was observed in the MED3
cell line. Data represent mean ± SEM of n ≥ 3 experiments, each experiment was performed in duplicate.
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analogues independent of MGMT expression (sulfoxide
IC50 15–40 μM whereas propargyl IC50 42.4-96.3 μM;
Figure 4C). To investigate whether BER was also able to
modulate response we determined the IC50 concentra-
tions for TMZ and the propargyl analogue when cells
were treated in combination with the PARP inhibitor
rucaparib (Additional file 13: Figure S9). There was con-
siderable chemosensitisation of TMZ by rucaparib in
MGMT expressing DAOY, MED3 and UW228-3 cell lines
(1.9 fold P = 0.02, 2.7 fold P = 0.002 and 2.2 fold P = 0.029
respectively; Table 2, Additional file 13: Figure S9). There
was however no potentiation of propargyl cytotoxicity in
combination with rucaparib (Table 2, Additional file 13:
Figure S9). These results suggest that in MB cells cytotox-
icity induced by the N-3 propargyl analogue is independ-
ent of MGMTand BER.
BCL2 ~26 kDa
BCL2A1 ~18 kDa 
MCL1 ~36 kDa
β-Tubulin ~50 kDa
A)
B)
C)
MED1DAOY UW228-3
IC50 = 270 nM IC50 = 300 nM IC50 = 420 nM
٭٭
٭
M
ED
1
D
A
O
Y
U
W
22
8-
3
β-Tubulin ~50 kDa
drug
drug + VPL
Figure 3 BCL2 family protein expression and functional analysis. BCL2A1 and ABCB1 limit response to ABT-737 but not obatoclax. (A) DAOY,
UW228-3 and MED1 cells were analysed by Western blotting for expression of anti-apoptotic BCL2 protein family member, BCL2 is expressed in
DAOY and MED-1 whereas no expression was observed in UW228-3 cells. MCL1 is expressed in DAOY and UW228-3 whereas MED-1 displayed no
expression. BCL2A1 was expressed at a low level in all three cell lines. β-tubulin served as a loading control. (B, C) Clonogenic survival of MB cells
in the presence of ABT-737 (B) or obatoclax (C) alone (dotted line) or in combination with 10 μM VPL (solid lines). Although IC50 values were not
reached, significant potentiation of ABT 737 function was observed at 50 μM concentration in combination with VPL in DAOY and MED1 cell lines
(unpaired student’s t-test, ٭٭ P = 0.03; ٭P = 0.02 respectively). Conversely, obatoclax IC50 values were in the nanomolar range for all 3 cell lines and
there was no potentiation when combined with VPL. Results from B and C represent mean ± SEM of n ≥ 3 experiments, all performed
in duplicate.
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Discussion
Benefit of adjuvant chemotherapy has been demonstrated
in children [10] particularly those under 3 years of age with
desmoplastic MB [3,9,10,15,16,25]. However, particularly in
high risk disease and in children under 3 years of age with
classic and anaplastic MB, chemotherapy failure due to
drug resistance is a recognised limitation to cure. There
are many aspects to chemotherapy resistance with protect-
ive mechanisms operating at each stage of the cytotoxic
process. We have sought here to investigate three basic
mechanisms that are key to effective chemotherapy cyto-
toxicity and resistance. Firstly, chemotherapeutic drugs
Figure 4 MGMT expression and response to TMZ, propargyl and sulfoxide imidazotetrazine analogues. (A) Relative levels of MGMT
expression were determined by Western blotting. DAOY, UW228-3 and MED3 cells showed high expression of MGMT while no expression was
observed in MED1 cells. (B) Chemical structure of TMZ, propargyl and sulfoxide, shows different N3 groups. (C) Clonogenic survival was
determined as in Figures 2, and 3, the data represent the IC50 values (mean ± SEM, n ≥ 3) TMZ inhibited survival in an MGMT-status dependent
manner (IC50 at 290–540 μM in MGMT positive cells (DAOY, UW228-3 and MED3) compared to 31 μM in MGMT negative MED1 cells). Propargyl
and sulfoxide derivatives of TMZ inhibited survival at 40–80 and 20–40 μM respectively in all cell lines, showing no dependence on MGMT
expression (unpaired student’s t-test, ٭٭٭ P < 0.0001; ٭P < 0.05).
Othman et al. Acta Neuropathologica Communications 2014, 2:57 Page 9 of 14
http://www.actaneurocomms.org/content/2/1/57
must remain in the tumour cell long enough to damage
DNA. Secondly, this damage must not be repaired. Thirdly,
downstream apoptosis mechanisms must be active. By
studying a set of MB cell lines we have demonstrated that
all of these processes reducing cytotoxicity are active, but
can be effectively inhibited or circumvented. Firstly, we
have demonstrated that > 40% of MB tumours express the
ABCB1 multi-drug transporter, which is able to export
many of the currently used chemotherapeutic drugs. There
was no difference in ABCB1 expression between the 4 mo-
lecular subtypes (data not shown). Importantly, our in vitro
data shows that export by ABCB1 could be inhibited
resulting in increased cytotoxicity. Secondly, we have
shown that although MGMT is expressed in the majority
of MB patients’ tumours, and is able to directly repair the
effects of DNA alkylating agents it cannot repair the effects
of two novel imidazotetrazine derivatives of TMZ (N-3
sulfoxide and N-3 propargyl) in MB cells. Thirdly, our data
indicate that, despite the expression of several BCL2 anti-
apoptotic family members, the BH3 mimetic obatoclax is
effective as a single agent in MB.
Multidrug transporters serve as a major mechanism of
defence in cancer chemotherapy. We hypothesise that the
treatment of MB with current chemotherapeutic drugs, al-
though effective as adjuvant therapy, leads to selection of
an ABCB1 transporter expressing sub-populations of cells
that in time can give rise to a more resistant tumour [63].
Importantly we have shown that in the DKFZ array
ABCB1 expression is associated with patients that fall into
the high risk category, which despite more aggressive ther-
apy have a poorer outcome [2,6,7]. The concentration of
etoposide used to achieve an IC50 in the ABCB1 positive
MED1 cell line was slightly above the concentration used
in clinic [64] while the MED3 IC50 was below the dose
limiting toxicity. The data suggest however that the appli-
cation of drugs that circumvent ABC transporters could
therefore represent a valid addition to current MB chemo-
therapy regimens, particularly in high risk MB. We have
used two inhibitors to overcome ABCB1 resistance in MB
cells. VPL (a calcium channel blocker) is a nonspecific
ABCB1 inhibitor and its low affinity to ABCB1 necessi-
tated use of a high dose to block ABCB1 in clinical trials,
resulting in unacceptable cardiac toxicity [65]. Vardenafil
is a phosphodiesterase type 5 inhibitor used to treat
children and infants with pulmonary arterial hypertension
and portal hypertension with minimal adverse effects at
concentrations above those indicated in our study [66,67].
It has been previously shown that vardenafil can speci-
fically block ABCB1 transporter function and enhance
blood–brain and blood–brain tumour barrier permeability
thereby enhancing delivery of herceptin to the brain in
mice bearing intracranial breast and lung cancer [68,69].
Our results showed that vardenafil enhances etoposide
cytotoxicity in ABCB1-expressing MB cell lines. The activ-
ity of vardenafil in each of our assays was equivalent to
that of the non-specific ABCB1 inhibitor verapamil. Thus,
vardenafil is a good potential candidate for combination
with current chemotherapeutics in patients with MB and
should now be tested in vivo in pre-clinical models.
Many efforts have been made towards development of
small molecules able to overcome the anti-apoptotic ac-
tivity of anti-apoptotic BCL2 family proteins. ABT-737
can overcome BCL2 and BCL-XL and is currently in
phase 1 clinical trial in small cell lung cancer (SCLC)
and chronic lymphocytic leukaemia [45,70]. Although
effective as a single agent in SCLC and leukaemia, ABT-
737 was not able to induce apoptosis as a single agent
in MB cells [46,71,72]. It has been previously shown
that ABT-737 function can be limited by BCL2A1 and
MCL1 protein expression [73-75]. Additionally, ABT-
737 has been demonstrated to be a substrate for ABCB1
and ABCC1 [47,76]. Our data suggest that ABT-737
induction of apoptosis in MB is dependent of both
BCL2A1 and ABCB1 protein expression. Using an
ABCB1 inhibitor did significantly potentiate the activity
of ABT-737 in MB cells; however the IC50 concentra-
tion was still not reached and these concentrations
would result in significant toxicity in vivo [77,78]. Oba-
toclax, on the other hand readily induced apoptosis, re-
gardless of BCL2A1 and ABCB1 protein expression, at
concentrations below the dose limiting toxicity concen-
tration observed in phase 1 clinical trial [39]. Obatoclax
has been used in a phase 1 clinical trial on advanced
leukemic patients where it showed minimum toxicity
and one patient had complete remission for 8 months
[44]. We believe obatoclax is a better candidate than
ABT-737 and may therefore represent a viable thera-
peutic option in MB patients.
Table 2 Toxicity and efficacy of TMZ and propargyl in combination with PARP inhibitor rucaparib in MB cell lines
Cell line IC50TMZ IC50TMZ + Rucaparib PF IC50Propargyl IC50Propargyl + Rucaparib PF
DAOY 540 ± 70.2 253 ± 35.1 1.9* 68.3 ± 26.2 47.9 ± 4.6 1.4
MED1 31 ± 12.4 26.8 ± 10.9 1.2 42.2 ± 9.5 43.4 ± 14 1.0
UW228-3 290 ± 14.8 129.5 ± 12 2.2* 96.3 ± 21.2 94.3 ± 38 1.0
MED3 332.9 ± 81.8 124.7 ± 55.3 2.7** 53.6 ± 16.8 56.3 ± 26.6 1.0
Abbreviation: IC50 = concentration resulting in 50% inhibition. PF = potentiation factor. ٭٭ P = 0.002; ٭P < 0.05 (unpaired student’s t-test). Result of n ≥ 3
experiments, all performed in duplicate.
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TMZ and Lomustine are alkylating agents commonly
used in clinic, however, the DNA damage cause by
these drugs can be repaired by MGMT [31]. Notably
only the IC50 concentration in the MGMT negative cell
lines (MED1) was below the maximum tolerated dose
of TMZ used in clinical trial [79]. Two novel imidazote-
trazine analogues N-3 sulfoxide and N-3 propargyl
TMZ derivatives used in this project were developed by
Pharminox in order to overcome direct DNA repair by
MGMT [31]. It is hypothesised that propargyl and sulf-
oxide analogues deliver cytotoxic lesions to O6-guanine
which cannot be removed by MGMT and both ana-
logues have been shown to cause double DNA strand
breaks leading to death in glioma cells. Overcoming
MGMT resistance in MB may be reliant on MB tu-
mours being proficient in mismatch repair. This is
potentially not an issue since MMR proficiency was re-
cently demonstrated in 74/74 primary MB tumours in a
study by von Bueren et al. [33]. In addition to MGMT
repair of O6-methylguanine, TMZ methylation at N7-
methylguanine and N3- methyladenine purines can also
be repaired by PARP through BER. Our data demon-
strate that sulfoxide and propargyl analogues are cyto-
toxic to all 4 MB cell lines regardless of MGMT
expression and that, unlike TMZ, the efficacy of the
propargyl analogue cannot be potentiated by the PARP
inhibitor rucaparib. This suggests that putative pro-
pargyl modification at N3 and N7 positions may not be
recognized by PARP, or cannot be repaired by BER.
Stability studies of the 2 analogues have shown that
N3-propargyl is more stable than TMZ in plasma
(100 minutes versus 30 minutes respectively); however,
the N3-sulfoxide analogue is extremely unstable in plasma
and hence unsuitable as a clinical candidate. Hence,
propargyl could be a good substitute for TMZ in recur-
rent and progressive MBs and may also be effective in
primary tumours.
Conclusions
We have tested three mechanisms of resistance to
chemotherapy mediated by ABCB1, MGMT and anti-
apoptotic BCL2 family members in MB cell lines. Tar-
geting these factors either by using an ABCB1inhibitor
(vardenafil), a novel agent that can circumvent DNA re-
pair (N3-propargyl analogue of TMZ) or a BH3 mimetic
to inhibit BCL2 anti-apoptotic proteins (obatoclax)
could all be viable therapeutic routes in this malignant
tumour in children. Our study of a small subset of MB
cell lines, however, indicates that these resistance mech-
anisms are not mutually exclusive. Hence, the next stage
should not only be to test the efficacy of these agents in
in vivo models but also to use them in combination. We
believe that such an approach will help to redefine MB
as a more chemo-sensitive disease.
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